Literature DB >> 15153155

Clinicopathological aspects of 18 Kaposi's sarcoma among 1055 Greek renal transplant recipients.

George Zavos1, John Bokos, Ioannis Papaconstantinou, John Boletis, Maria Gazouli, John Kakisis, Anastassios Zografidis, Alkiviadis Kostakis.   

Abstract

The incidence of Kaposi's sarcoma (KS) in transplant recipients is 400-500 times greater than that in the general population, and is rising within the transplant population. In this study, between March 1983 and December 2001, 1055 cases were recorded where KS developed in 18 patients (1.7%) who were treated with AZA + CsA + MP, MMF + CsA + MP, MMF + Tac + MP, CsA + MP, or AZA + MP therapy (AZA, azathioprine; CsA, cyclosporine A; MP, methylprednisolone; MMF, mycophenolate mofetil; Tac, Tacrolimus). In the present study, 18 renal transplant recipients who developed KS and were followed and analyzed. Analysis revealed that a continuous state of immunodeficiency is important for the development of KS. Prognosis in patients with KS limited to the skin is favorable, while visceral involvement is associated with high mortality. Transplant function is well preserved in most of the cases. The association, previously described, between human herpesvirus 8 (HHV8) and transplant-associated KS also exists in the studied population.

Entities:  

Mesh:

Year:  2004        PMID: 15153155     DOI: 10.1111/j.1525-1594.2004.00019.x

Source DB:  PubMed          Journal:  Artif Organs        ISSN: 0160-564X            Impact factor:   3.094


  5 in total

1.  A case of exogenous corticosteroid-induced Kaposi's sarcoma that developed after a cure of endogenous hypercortisolism.

Authors:  Soyeon Yoo; Shinhang Moon; Sang-Ouk Chin; Sang-Ah Lee; Changlim Hyun; Gwanpyo Koh
Journal:  Int J Clin Pharm       Date:  2015-08-19

2.  Benign and malignant skin lesions in renal transplant recipients.

Authors:  H Ghaninejad; A H Ehsani; M Ghiasi; P Noormohammadpour; E Najafi; G Naderi; M Ganji; M Mirnezami; R Nezami; P Kiani
Journal:  Indian J Dermatol       Date:  2009-07       Impact factor: 1.494

3.  Seroprevalence of Human herpesvirus 8 (HHV-8) and incidence of Kaposi's sarcoma in Iran.

Authors:  Somayeh Jalilvand; Zabihollah Shoja; Talat Mokhtari-Azad; Rakhshandeh Nategh; Ahmad Gharehbaghian
Journal:  Infect Agent Cancer       Date:  2011-04-28       Impact factor: 2.965

4.  An Update on Kaposi's Sarcoma: Epidemiology, Pathogenesis and Treatment.

Authors:  Paul Curtiss; Lauren C Strazzulla; Alvin E Friedman-Kien
Journal:  Dermatol Ther (Heidelb)       Date:  2016-11-01

5.  The Spectrum of Underlying Causes of Iatrogenic Kaposi's Sarcoma in a Large Series: A Retrospective Study.

Authors:  Can Baykal; Tugba Atci; Nesimi Buyukbabani; Armagan Kutlay
Journal:  Indian J Dermatol       Date:  2019 Sep-Oct       Impact factor: 1.494

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.